ENDRA Life Sciences Inc. 8-K

What Happened
ENDRA Life Sciences (NDRA) announced that on July 8, 2026 Nasdaq notified the company it has regained compliance with the $2,500,000 minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), effective July 1, 2026. The company had previously been notified on April 20, 2026 that its 2025 Form 10-K reported equity below the required minimum, requested a hearing on April 27, and attended a hearing on May 28, 2026.

Key Details

• Nasdaq informed ENDRA on April 20, 2026 that reported stockholders’ equity for year ended Dec 31, 2025 was below the $2,500,000 minimum.
• ENDRA requested a hearing April 27, 2026; hearing occurred May 28, 2026.
• Nasdaq’s July 8, 2026 Notice states the company regained compliance as of July 1, 2026.
• Per Nasdaq Listing Rule 5815(d)(4)(A), ENDRA will be subject to a Discretionary Panel Monitor for one year from July 1, 2026; if found out of compliance again during that period, Nasdaq may issue a delist determination without granting additional cure time or allowing a compliance plan.

Why It Matters
Regaining compliance avoids immediate delisting and keeps ENDRA’s shares listed on Nasdaq for now, but the one-year discretionary monitor places the company under heightened scrutiny. If another listing rule deficiency occurs during the monitoring year, Nasdaq can move directly toward delisting without the usual opportunity to propose a compliance plan or cure the deficiency—making upcoming financial reports and any Nasdaq notices especially important for investors monitoring liquidity, equity levels, and listing risk.